AUR-AFSO-TTP1-A-8-0-R-A741-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.450
- ALLOGRAFT_REJECTION+0.390
- IL6_JAK_STAT3_SIGNALING+0.390
- INFLAMMATORY_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.380
- PANCREAS_BETA_CELLS+0.280
- ANDROGEN_RESPONSE+0.260
- IL2_STAT5_SIGNALING+0.230
- PROTEIN_SECRETION+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- MYC_TARGETS_V2-0.430
- ADIPOGENESIS-0.400
- MYOGENESIS-0.390
- BILE_ACID_METABOLISM-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- PEROXISOME-0.350
- FATTY_ACID_METABOLISM-0.340
- CHOLESTEROL_HOMEOSTASIS-0.330
- DNA_REPAIR-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0054_T1A_RNA | — | A | 0.875 |
| 2 | b9389390-aa03-406c-957e-2bc264f9468e | — | — | 0.851 |
| 3 | SRR8518220 | — | D | 0.846 |
| 4 | c22c07cb-8215-47e8-9525-074fda8d7d59 | — | — | 0.845 |
| 5 | SRR8942978 | — | — | 0.836 |
| 6 | s0122308 | — | — | 0.826 |
| 7 | AUR-AFE5-TTP1-A-1-0-R-A741-41 | — | D | 0.811 |
| 8 | SRR12696760 | — | — | 0.804 |
| 9 | TCGA-44-6778-01A-11R-1858-07 | — | cohortMD2 | 0.799 |
| 10 | TCGA-44-3918-01A-01R-A278-07 | — | cohortMD2 | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |